Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

American Journal of Cardiology

Volumn 87, Issue 5 SUPPL. 1, 2001, Pages 28-32

  McTaggart, Fergus ^a   Buckett, Linda ^a   Davidson, Robert ^a   Holdgate, Geoffry ^a   McCormick, Alex ^a   Schneck, Dennis ^a   Smith, Graham ^a   Warwick, Michael ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450 3A4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANIMAL CELL; ATHEROGENESIS; CHOLESTEROL SYNTHESIS; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME ACTIVE SITE; FIBROBLAST; HUMAN; HUMAN CELL; HYDROPHILICITY; LIVER CELL; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0035825928     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9149(01)01454-0     Document Type: Conference Paper

References (8)

1. Lowering LDL cholesterol: Questions from recent meta-analyses and subset analyses of clinical trial data: Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease
2. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells
3. Pharmacological properties of ZD4522: A new HMG-CoA reductase inhibitor
4. Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat
5. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522
6. Drug treatment of lipid disorders
7. ZD4522: An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems